+

WO2006005583A3 - Secreted polypeptide species involved in multiple sclerosis - Google Patents

Secreted polypeptide species involved in multiple sclerosis Download PDF

Info

Publication number
WO2006005583A3
WO2006005583A3 PCT/EP2005/007561 EP2005007561W WO2006005583A3 WO 2006005583 A3 WO2006005583 A3 WO 2006005583A3 EP 2005007561 W EP2005007561 W EP 2005007561W WO 2006005583 A3 WO2006005583 A3 WO 2006005583A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
secreted polypeptide
species involved
polypeptide species
polypeptides
Prior art date
Application number
PCT/EP2005/007561
Other languages
French (fr)
Other versions
WO2006005583A2 (en
Inventor
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Original Assignee
Geneprot Inc
Lydie Bougueleret
Isabelle Cusin
Eve Mahe
Anne Niknejad
Samia Reffas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneprot Inc, Lydie Bougueleret, Isabelle Cusin, Eve Mahe, Anne Niknejad, Samia Reffas filed Critical Geneprot Inc
Publication of WO2006005583A2 publication Critical patent/WO2006005583A2/en
Publication of WO2006005583A3 publication Critical patent/WO2006005583A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Rehabilitation Therapy (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention discloses human secreted polypeptides whose concentration is specifically altered in the serum obtained from individuals with multiple sclerosis, when compared to the same from individuals free of multiple sclerosis. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis and prognosis of multiple sclerosis, and for drug development.
PCT/EP2005/007561 2004-07-12 2005-07-12 Secreted polypeptide species involved in multiple sclerosis WO2006005583A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58724904P 2004-07-12 2004-07-12
US60/587,249 2004-07-12

Publications (2)

Publication Number Publication Date
WO2006005583A2 WO2006005583A2 (en) 2006-01-19
WO2006005583A3 true WO2006005583A3 (en) 2006-07-13

Family

ID=35614590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007561 WO2006005583A2 (en) 2004-07-12 2005-07-12 Secreted polypeptide species involved in multiple sclerosis

Country Status (1)

Country Link
WO (1) WO2006005583A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7123684B2 (en) 2002-11-27 2006-10-17 Hologic, Inc. Full field mammography with tissue exposure control, tomosynthesis, and dynamic field of view processing
JP2009538416A (en) * 2006-05-26 2009-11-05 フェノメノーム ディスカバリーズ インク Biomarker and method for diagnosing multiple sclerosis
WO2008134577A1 (en) * 2007-04-25 2008-11-06 Reed Guy L Method of increasing plasmin activity through antiplasmin conversion
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
WO2010049103A1 (en) * 2008-10-31 2010-05-06 Eth Zurich Soluble truncated apom proteins and medical uses thereof
KR101320633B1 (en) * 2011-05-25 2013-10-30 엠앤디 (주) Method of providing information for diagnosis of cancer using quantitative realtime PCR and diagnostic kit comprising thereof
CA2846667A1 (en) 2011-09-06 2013-03-14 Guy L. Reed Serpinf2-binding molecules and methods of use
WO2016106186A1 (en) 2014-12-22 2016-06-30 Translational Sciences, Inc. Prophylaxis of thrombosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059604A2 (en) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059604A2 (en) * 2001-01-26 2002-08-01 Oxford Glycosciences (Uk) Ltd Diagnosis and treatment of multiple sclerosis

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ 1 July 2004 (2004-07-01), "Human NOVX polypeptide #90", XP002365253, retrieved from EBI Database accession no. ADM93548 *
DATABASE GENESEQ 16 January 2002 (2002-01-16), "Human breast cancer-associated protein isoform, BPI-248 peptide #1", XP002365442, retrieved from EBI Database accession no. AAU68420 *
DATABASE GENESEQ 16 January 2002 (2002-01-16), "Human breast cancer-associated protein isoform, BPI-248 peptide #2", XP002365443, retrieved from EBI Database accession no. AAU68421 *
DATABASE GENESEQ 3 June 2004 (2004-06-03), "Human angiogenesis-related transgelin 2 (TAGLN2) protein", XP002365254, retrieved from EBI Database accession no. ADL35877 *
FANGERAU T ET AL: "Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria", ACTA NEUROLOGICA SCANDINAVICA, vol. 109, no. 6, June 2004 (2004-06-01), pages 385 - 389, XP002365251, ISSN: 0001-6314 *

Also Published As

Publication number Publication date
WO2006005583A2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
WO2006073941A3 (en) Polypeptides that bind br3 and uses thereof
PH12012501006A1 (en) Compositions and methods relating to anti-igf-1 receptor antibodies
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
MX2009013824A (en) Antigen binding proteins that bind par-2.
WO2004075861A3 (en) Recombinant adeno-associated virus production
WO2003060090A3 (en) Novel cytokine zcytor17 ligand
GEP20115226B (en) P-cadherin antibodies
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
WO2003089616A3 (en) Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
WO2006055638A3 (en) Fully human monoclonal antibodies to il-13
WO2006007853A3 (en) A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
UA96122C2 (en) Anti-il-22ra antibody or antigen binding fragment thereof and methods of use
DE60331677D1 (en) KIT FOR THE STUDY OF HUMAN LOW MOLECULAR WEIGHT CD14 AND ANTIBODIES
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
WO2003065003A3 (en) Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
WO2004113500A3 (en) B7s1: an immune modulator
WO2006005583A3 (en) Secreted polypeptide species involved in multiple sclerosis
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2005015206A3 (en) Secreted polypeptide species associated with cardiovascular disorders
WO2005008253A3 (en) Stable compositions for measuring human natriuretic peptides
WO2005000876A3 (en) Ring finger family proteins and uses related thereto
WO2008142664A3 (en) Exposed thymidine kinase 1 peptides, ligands and methods employing the same
WO2006069765A3 (en) Secreted polypeptide species involved in multiple sclerosis
WO2004083241A3 (en) Btc-interacting proteins and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载